Virax Biolabs Group Limited (VRAX)
USD 2.37
(39.41%)
USD 2.37
(39.41%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | -6.24 Million | -4.17 Million | -809.06 Thousand | -590.18 Thousand | -744.61 Thousand |
| Net Income | -6.73 Million | -5.45 Million | -1.7 Million | -650.98 Thousand | -739.46 Thousand |
| Depreciation & Amortization | 103.09 Thousand | - | - | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.01 Million | 1.73 Million | 290.36 Thousand | - | - |
| Change in working capital | -1.12 Million | -216.27 Thousand | 644.39 Thousand | 59.61 Thousand | -96.82 Thousand |
| Other non-cash items | 115.5 Thousand | -260.59 Thousand | -32.07 Thousand | 1187.00 | 91.67 Thousand |
| Investing Cash Flow | -1.16 Million | -178.4 Thousand | - | - | - |
| Investments in PPE | -1.16 Million | -178.4 Thousand | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -211.95 Thousand | -178.4 Thousand | - | - | - |
| Financing Cash Flow | 1.64 Million | 13.68 Million | 813.2 Thousand | 585.19 Thousand | 704.63 Thousand |
| Debt repayment | -206.27 Thousand | -146.25 Thousand | -100 Thousand | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 234.00 | 13.65 Million | 519.61 Thousand | 403.21 Thousand | - |
| Other Financing Activities | -18.29 Thousand | 180.85 Thousand | 293.59 Thousand | 181.98 Thousand | 704.63 Thousand |
| Accounts receivables | -217.84 Thousand | - | 928.00 | -928.00 | - |
| Accounts payables | -572.24 Thousand | 33.94 Thousand | 641.15 Thousand | 81.61 Thousand | -96.82 Thousand |
| Inventory | -60.38 Thousand | 20.95 Thousand | 121.00 | -21.07 Thousand | - |
| Other working capital | -38.25 Thousand | -237.22 Thousand | 2185.00 | - | - |
| Cash at beginning of period | 9.35 Million | 21.75 Thousand | 17.62 Thousand | 22.6 Thousand | 62.58 Thousand |
| Cash at end of period | 3.58 Million | 9.35 Million | 21.75 Thousand | 17.62 Thousand | 22.6 Thousand |
| Capital Expenditure | -1.16 Million | -178.4 Thousand | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -5.76 Million | 9.33 Million | 4135.00 | -4988.00 | -39.97 Thousand |
| Free Cash Flow | -7.41 Million | -4.35 Million | -809.06 Thousand | -590.18 Thousand | -744.61 Thousand |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.73 Million | -3.82 Million | -2.9 Million | -4.01 Million | -5.45 Million | -1.44 Million |
| Depreciation & Amortization | 103.09 Thousand | 85.38 Thousand | 17.71 Thousand | - | - | - |
| Deferred income taxes | - | - | -378.83 Thousand | - | - | - |
| Stock-based compensation | 1.01 Million | 925.7 Thousand | 86.26 Thousand | 1.5 Million | 1.73 Million | 248.97 Thousand |
| Change in working capital | -1.12 Million | 82.23 Thousand | -585.81 Thousand | 875.41 Thousand | -216.27 Thousand | -1.09 Million |
| Other non-cash items | 115.5 Thousand | -58.78 Thousand | 312.65 Thousand | 865.11 Thousand | -260.59 Thousand | 607.93 Thousand |
| Investing Cash Flow | -1.16 Million | -456.26 Thousand | -708.18 Thousand | -178.4 Thousand | -178.4 Thousand | - |
| Investments in PPE | -1.16 Million | -459.92 Thousand | -708.18 Thousand | -178.4 Thousand | -178.4 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 3653.00 | -215.6 Thousand | -178.4 Thousand | -178.4 Thousand | - |
| Financing Cash Flow | 1.64 Million | 1.72 Million | -78.81 Thousand | 6.84 Million | 13.68 Million | 6.84 Million |
| Debt repayment | -206.27 Thousand | -3656.00 | -146.25 Thousand | -146.25 Thousand | -146.25 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -85.5 Thousand | - | - | - | - |
| Common Stock Issuance | 234.00 | 1.87 Million | 234.00 | 7.09 Million | 13.65 Million | 6.55 Million |
| Other Financing Activities | -18.29 Thousand | 1.81 Million | 67.2 Thousand | -398.94 Thousand | 180.85 Thousand | 287.3 Thousand |
| Accounts receivables | -217.84 Thousand | -34.48 Thousand | -183.36 Thousand | - | - | - |
| Accounts payables | -572.24 Thousand | -522.98 Thousand | -49.26 Thousand | 390.08 Thousand | 33.94 Thousand | -390.08 Thousand |
| Inventory | -60.38 Thousand | -35.87 Thousand | -24.5 Thousand | - | 20.95 Thousand | 20.95 Thousand |
| Other working capital | -38.25 Thousand | 118.1 Thousand | -328.68 Thousand | 485.33 Thousand | -237.22 Thousand | -722.55 Thousand |
| Cash at beginning of period | 9.35 Million | 5.1 Million | 9.35 Million | 4.57 Million | 21.75 Thousand | 21.75 Thousand |
| Cash at end of period | 3.58 Million | 3.58 Million | 5.1 Million | 9.35 Million | 9.35 Million | 4.57 Million |
| Capital Expenditure | -1.16 Million | -459.92 Thousand | -708.18 Thousand | -178.4 Thousand | -178.4 Thousand | - |
| Effect of forex changes on cash | - | - | 9.35 Million | -9.35 Million | - | - |
| Net cash flow / Change in cash | -5.76 Million | -1.51 Million | -4.24 Million | 4.78 Million | 9.33 Million | 4.54 Million |
| Free Cash Flow | -7.41 Million | -3.24 Million | -4.16 Million | -2.06 Million | -4.35 Million | -2.29 Million |
IHICY
7242
SGAMY
000633
6485
3191